19 February 2016 - Spectrum Pharmaceuticals has announced that the U.S. FDA has accepted the EOquin (apaziquone for intravesical instillation) New Drug Application (NDA) for review. The FDA also indicated that it plans to hold an advisory committee meeting regarding the NDA. The FDA has set a target action date under the Prescription Drug User Fee Act of December 11, 2016.

For more details, go to: http://investor.sppirx.com/releases.cfm